Peripheral Neuropathy PN can be caused by many agents, common ones include alcohol, diabetes, chronic renal failure Infections such as varicella (shingles),

Slides:



Advertisements
Similar presentations
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Advertisements

Palumbo A et al. Proc ASH 2013;Abstract 536.
 Irritation or damage to nerves outside the brain and spinal cord  Causes difficulty in communication between nerves or group of nerves.
Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Ileana Howard, MD Rehabilitation Care Services VA Puget Sound Health Care October 28, 2014.
© 2006 National Lipid Association Statin Safety: Key Conclusions and Recommendations of the NLA.
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.
Drugs Used in the Treatment of Multiple Myeloma Myeloma Canada National Conference 2011-September-24 Toronto, Ontario Carlo De Angelis, RPh, PharmD Clinical.
1 WHY PHYSICAL FITNESS?. 2 CHANGING LIFESTYLES The recent widespread interest in health and preventive medicine has led to a tremendous increase in the.
COMMON LIFESTYLE DISEASES
1. Cholesterol is a fat FALSE Cholesterol is not used for energy like a fat Cholesterol is not digested like a fat Cholesterol does not have the nutritional.
Adult Immunization 2010 Herpes Zoster (Shingles) Segment This material is in the public domain This information is valid as of May 25, 2010.
MANAGING FATIGUE during treatment Since fatigue is the most common symptom in people receiving chemotherapy, patients should learn ways to manage the fatigue.
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
SEASONAL AFFECTIVE DISORDER (S.A.D). WHAT IS SEASONAL AFFECTIVE DISORDER? Seasonal affective disorder (SAD) is a kind of depression that occurs at a certain.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Peritoneal Dialysis End Stage Renal Disease Causes and Treatment Methods.
Glucose Control and Monitoring
Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.
Wellness and Cancer Oncology Liaison Nurses Bon Secours Hospital Kate Murphy & Roisin O’Sullivan.
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden.
Copyright © 2008 Delmar Learning. All rights reserved. Unit 37 Alternative, Complementary, and Integrative Approaches to Patient Care.
Dr. John Hayes Jr. Discusses the Diagnosis of Peripheral Neuropathy.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
Targeting Taxane-Induced NeuropathyWith Exercise Constance Visovsky PhD, RN, APRN-NP Associate Dean of Student Affairs & Director Community Engagement.
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.
ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:
Hepatitis C.
Men’s Health Week June Underground Atlanta Eat Street Food Truck Wednesday Eat Street Food Truck Wednesday.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
An unpleasant sensory or emotional experience associated with actual or potential tissue damage The World Health Organization (WHO) has stated that pain.
Renal Complications Associated with Diabetes By Gabriella Benavides FNP-BC.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Exercise Training on Depressive Symptoms.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risk of End-Stage Renal Disease Following Live Kidney.
Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Duloxetine on Pain, Function, and Quality.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.
Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation.
Cardiac Emergency/Disorders
Copyright © 1998 American Medical Association. All rights reserved.
Dr John Cox Diabetes in Primary Care Conference Cork
CIPN: Considerations for Drug Development
Copyright © 2007 American Medical Association. All rights reserved.
Concussions 101: What Every Athlete Needs to Know
Palumbo A et al. Proc ASH 2012;Abstract 200.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2000 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Mateos MV et al. Proc ASH 2013;Abstract 403.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Andrzej Jakubowiak  Seminars in Hematology 
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Copyright © 2011 American Medical Association. All rights reserved.
Program Goals. Out of the Periphery and Into Comprehensive Care: Managing Diabetic Peripheral Neuropathy.
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Supported in part by Arkansas Blue Cross and Blue Shield
Dr. John Hayes Jr Discusses Some Causes of Peripheral Neuropathy
Presentation transcript:

Peripheral Neuropathy PN can be caused by many agents, common ones include alcohol, diabetes, chronic renal failure Infections such as varicella (shingles), HIV, occasionally EBV, CMV Also toxins such as heavy metals (lead, arsenic, mercury) Many chemotherapy drugs About 10% of people with myeloma have PN before any treatment

Peripheral Neuropathy Typical chemotherapy related neuropathy differs from that of other forms of PN Glove and stocking distribution Generally sensory, i.e. what a person feels, rather than motor, i.e. what a person can functionally do Estimates run that over 1/3 of chemotherapy drugs can cause PN Risk of PN often dose related, how much drug a pt. receives over time

In patients with myeloma, several drugs associated with PN: Thalidomide- PN related to both dose and time on continuous treatment Bortezomib-risks for PN development include –Intravenous administration –Twice weekly versus weekly –Combination with other drugs: egg doxorubicin, platinum, lenalidomide, thalidomide

vincristine: part of VAD regimen, used much less frequently now for myeloma; often improves with time Cisplatin-part of DT-PACE regimen-also associated with tinnitus

“coasting” can occur, i.e. signs and symptoms continue to develop after therapy stops (particularly true for bortezomib) Genetic predisposition may occur— estimated that 1% of myeloma patients are extremely susceptible to bortezomib related PN and may experience this after one dose

ASCO Guidelines for the Treatment of PN Examined 250 trials over twenty years; 42 high quality trials selected to see what drugs helped (or didn’t) (JCO 4/14/2014

Not recommended: Hershman et al JCO 32: , 2014

Recommended: Duloxetine (Cymbalta) Tricyclic antidepressants-nortryptiline (pamelor), amitr1ptyline Gabapentin Topical gel-baclofen, amitriptyline, ketamine

Drug alternatives Data suggests acupuncture lowers nausea in pts undergoing chemotherapy Ask your provider for a referral Some insurance plans cover acupuncture Contact: National Certification Commission for Acupuncture and Oriental Medicine. The website is:

Steroid induced myopathy This is defined as weakness that develops in “large muscle groups” related to steroids First studied in 1959 Appears to be more common when fluorinated steroids used, DEXAMETHASONE! Any type of steroid can cause this (even inhalers)

Typically develops in weeks to months Acute form also exists (symptoms occur in matter of 5-7 days) Symptoms include increasing weakness of upper arms, thighs Difficulty rising from a chair, walking up stairs, lifting more than very light objects repetitively

Treatment Recovery is possible but takes weeks to months Reduce or discontinue steroids whenever possible Every other day dosing of steroid Change to less toxic form (e.g. dexamethasone to prednisone) Aerobic exercise, resistance training

No medicines appear to be useful Ineffective treatments include: –Potassium and phosphorus supplements –Dilantin (phenytoin) –High dose Vitamin E –Anabolic steroids (what body builders, athletes use)

SUPPLEMENTS IP-6

Copyright © 2014 American Medical Association. All rights reserved. From: Trends in Alternative Medicine Use in the United States, : Results of a Follow-up National Survey JAMA. 1998;280(18): doi: /jama Figure 2.—Estimated annual out-of-pocket expenditures for alternative therapies vs conventional medical services, United States, Data are from the Health Care Financing Administration, United States.RBRVS indicates Resource-Based Relative Value Scale. Figure Legend :

Use of alternative medications very common among pts receiving chemotherapy Richardson et al JCO 18:2505, 2000

Caveats: Some supplements may interfere with chemotherapy agents Blood 2009, 113: 5927

Diet: eating from the FDA guidelines Exercise: minutes 3-5x weekly Meditation: appears to improve symptoms such as nausea, fatigue Other interventions: music, acupuncture, volunteer activities, sun exposure Ask your doctor their opinion regarding your supplements Make sure they know you are taking them

Thanks!